(Q37636156)

21 August 2017

1 reference

title

Tetrabenazine. (English)

1 reference

21 August 2017

Anna Rita Bentivoglio

object named as

Anna Rita Bentivoglio

series ordinal

2

0 references

Alfonso Fasano

object named as

Alfonso Fasano

series ordinal

1

0 references

language of work or name

English

0 references

publication date

1 December 2009

1 reference

Expert Opinion on Pharmacotherapy

21 August 2017

1 reference

21 August 2017

10

1 reference

21 August 2017

17

1 reference

21 August 2017

2883-2896

1 reference

The effect of tetrabenazine in some hyperkinetic syndromes

21 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656560903386292

The pharmacokinetics of tetrabenazine and its hydroxy metabolite in patients treated for involuntary movement disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903386292

Synaptic vesicular monoamine transporter expression: distribution and pharmacologic profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903386292

Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903386292

Tetrabenazine-induced depletion of brain monoamines: characterization and interaction with selected antidepressants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903386292

The regionalization of [3H]dihydrotetrabenazine binding sites in the mouse brain and its relationship to the distribution of monoamines and their metabolites.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903386292

Depletion of monoamine transmitters by tetrabenazine in brain tissue in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903386292

Tetrabenazine has properties of a dopamine receptor antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903386292

Tetrabenazine induces acute dystonic reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903386292

A double-blind trial of tetrabenazine, thiopropazate, and placebo in patients with chorea

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903386292

The mode of action of tetrabenazine on peripheral noradrenergic nerves

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903386292

Dopaminergic signaling and striatal neurodegeneration in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903386292

Repetitive administration of tetrabenazine induces irreversible changes in locomotion and morphology of the substantia nigra in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903386292

Pathophysiology of Huntington's disease: from huntingtin functions to potential treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903386292

The current clinical management of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903386292

A Double Blind Trial of Lithium Carbonate and Haloperidol in Huntington's Chorea

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903386292

Tiapride in the treatment of Huntington's chorea

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903386292

A double blind trial of sulpiride in Huntington's disease and tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903386292

Tiapride versus placebo: a double-blind comparative study in the management of Huntington's chorea

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903386292

Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903386292

Pathophysiology of chorea and bradykinesia in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903386292

Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903386292

Tetrabenazine and movement disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903386292

Tetrabenazine treatment for Huntington's disease-associated chorea

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903386292

Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903386292

A study of chorea after tetrabenazine withdrawal in patients with Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903386292

Long-term effects of tetrabenazine in hyperkinetic movement disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903386292

Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903386292

The long-term effect of tetrabenazine in the management of Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903386292

Huntington's disease: clinical correlates of disability and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903386292

Drug Insight: from disturbed motility to disordered movement--a review of the clinical benefits and medicolegal risks of metoclopramide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903386292

Tardive stereotypy and other movement disorders in tardive dyskinesias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903386292

Nithsdale Schizophrenia Surveys 23: movement disorders. 20-year review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903386292

Treatment of tardive dyskinesia. I. Clinical efficacy of a dopamine-depleting agent, tetrabenazine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903386292

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903386292

Presynaptic catecholamine antagonists as treatment for Tourette syndrome. Effects of alpha methyl para tyrosine and tetrabenazine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903386292

Effect of tetrabenazine on tics and sleep of Gilles de la Tourette's syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903386292

Tetrabenazine treatment in movement disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903386292

Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903386292

Idiopathic torsion dystonia (dystonia musculorum deformans). A review of forty-two patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903386292

The treatment of severe dystonia in children and adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903386292

Management of status dystonicus: our experience and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903386292

Segmental myoclonus. Clinical and pharmacologic study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903386292

Tetrabenazine in the treatment of severe pediatric chorea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903386292

Tetrabenazine in the treatment of hyperkinetic movement disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903386292

Is history of depression a contraindication to treatment with tetrabenazine?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903386292

Severe hyperthermia during tetrabenazine therapy for tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903386292

Neuroleptic Malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903386292

Tetrabenazine as a cause of neuroleptic malignant syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903386292

A case of tetrabenazine-induced neuroleptic malignant syndrome after prolonged treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903386292

Pharmacological management of Huntington's disease: an evidence-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903386292

Treatment of the symptoms of Huntington's disease: preliminary results comparing aripiprazole and tetrabenazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903386292

Aripiprazole is associated with early onset of Tardive Dyskinesia like presentation in a patient with ABI and psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903386292

GPi-DBS in Huntington's disease: results on motor function and cognition in a 72-year-old case

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903386292

Short-term effects of tetrabenazine on chorea associated with Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903386292

The trial use of clozapine for abnormal involuntary movement disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903386292

10.1517/14656560903386292

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference

PubMed ID

19929707